纳洛酮和醒脑静联合用药在急性酒精中毒的急诊治疗中的效果

Effect of the combination of naloxone and Xingnaojing in the emergency treatment of acute alcohol intoxication

目的研究分析纳洛酮和醒脑静联合用药在急性酒精中毒的急诊治疗中的效果。方法回顾性分析2015年2月至2017年2月来我院进行急性酒精中毒治疗的100例患者的临床资料,按照治疗方法分为观察组和对照组,每组50例。对照组在常规治疗基础上采用纳洛酮治疗,观察组在常规治疗基础上采用纳洛酮联合醒脑静治疗,比较两组患者的临床治疗效果,药物起效、意识恢复、症状改善及症状消失时间及不良反应发生情况。结果观察组患者的临床治疗有效率为100.0%,明显高于对照组的92.0%(P<0.05)。观察组患者的药物起效、意识恢复、症状改善及症状消失时间均短于对照组(P<0.05)。观察组患者不良反应总发生率为16.0%(8/50),低于对照组的38.0%(19/50)(P<0.05)。结论在治疗急性酒精中毒患者时,纳洛酮联合醒脑静治疗效果显著,患者临床症状消失时间缩短,不良反应发生率降低,值得临床推广。

Objective To study the effect of combination of naloxone and Xingnaojing in the emergency treatment of acute alcohol intoxication. Methods From February 2015 to February 2017, the clinical date of 100 cases of patients with acute alcohol intoxication treated in our hospital were analzed retrospectively, and divided into observation group and control group according to the treatment methods, with 50 cases in each group. The control group received naloxone on the basis of routine treatment, while the observation group accepted naloxone combined with Xingnaojing on the basis of routine treatment. The clinical effect, time of drug onset, recovery of consciousness, improvement of symptoms and disappearance of symptoms and incidence of adverse reactions of the two groups were compared. Results The clinical efficacy of the observation group was 100.0%, which was significantly higher than 92.0% of the control group（P〈0.05）. The time of drug onset, recovery of consciousness, improvement of symptoms and disappearance of symptoms in the observation group were shorter than those in the control group（P〈0.05）. The total incidence of adverse reactions in the observation group was 16.0%（8/50）, which was lower than 38.0%（19/50） of the control group（P〈0.05）. Conclusion In the treatment of patients with acute alcohol intoxication, naloxone combined with Xingnaojing has good effect, which can shorten the disappearance time of clinical symptoms and reduce the incidence of adverse reactions, it is worthy of the clinical promotion.